173
Participants
Start Date
July 7, 2020
Primary Completion Date
August 30, 2024
Study Completion Date
August 30, 2024
Etrumadenant
Etrumadenant is an A2aR and A2bR antagonist
Zimberelimab
Zimberelimab is an anti-PD-1 antibody
Quemliclustat
Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
Enzalutamide
Enzalutamide is an androgen receptor inhibitor
Docetaxel
Docetaxel is type of chemotherapy
SG
Sacituzumab govitecan is an antibody-drug conjugate
Wilmot Cancer Institute Oncology, University of Rochester, Rochester
Johns Hopkins University, Baltimore
Florida Cancer Specialists Panhandle, Tallahassee
Florida Cancer Specialists East, West Palm Beach
Florida Cancer Specialists North, St. Petersburg
Florida Cancer Specialists South, Sarasota
Tennessee Oncology - Nashville, Nashville
Tennessee Oncology - Chattanooga, Chattanooga
Cleveland Clinic, Cleveland
Affinity Health Hope & Healing Cancer Services, Hinsdale
Northwestern University Feinberg School of Medicine, Chicago
MD Anderson Cancer Center, Houston
The Oncology Institute of Hope & Innovation, Cerritos
The University of California, Los Angeles, Encino
The University of California, Irvine Medical Center, Orange
Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane
New York University, Langone Health, New York
Juravinski Cancer Center, Hamilton
Centre hospitalier de l'Université de Montréal (CHUM) Centre de Recherche, Montreal
Lead Sponsor
Collaborators (1)
Gilead Sciences
INDUSTRY
Arcus Biosciences, Inc.
INDUSTRY